Hvivo reports record revenue in first half of the year

Hvivo, a Dublin and London-listed pharmaceutical services company, reported a record revenue for the first half of the year, continuing its momentum in the market. Specialising in testing infectious and respiratory disease products, Hvivo announced that revenue for the six months ending on June 20th was expected to reach £35.6 million. This marks a 30 per cent increase from the £27.3 million recorded during the same period last year.

The company’s revenue surge was driven by several projects being completed ahead of schedule. Hvivo’s weighted contracted order book stood at £71 million at the end of the six months, compared to £78 million in 2023. Earnings before interest, tax, depreciation, and amortisation (EBITDA) improved to 24 per cent, up from 19.1 per cent in the first half of 2023. Additionally, the company reported a cash reserve of £37.1 million and paid an annual dividend of £1.4 million to shareholders in May.

Hvivo’s quarantine facility in Canary Wharf is now fully operational, featuring advanced laboratories, an outpatient unit, and corporate offices. This development provides the company with increased quarantine capacity, supporting future growth. The expanded facilities and containment level three capability will enable Hvivo to extend its core human challenge trial to include new pathogen models. From July onwards, the company will operate solely from its Canary Wharf quarantine site.

The company remains on track to meet its full-year revenue guidance of £62 million, with EBITDA margins expected to be at the higher end of market expectations. Chief Executive Yamin “Mo” Khan credited the team’s hard work, flexibility, and commitment for the successful results of the first half of 2024. Despite the significant activity involved in the buildout and move to the new facility, Hvivo not only increased its revenue significantly but also improved its margins. Operating three different facilities concurrently boosted revenues for H1 2024, creating a strong first half weighting.

Khan expressed optimism for Hvivo’s future as the company welcomed its first volunteers into the new Canary Wharf facility, the world’s largest human challenge trial unit. He believes the foundation has been laid for strong performance in the coming months and years.

Hvivo was formed when Chairman Cathal Friel merged his pharma services business, formerly known as Open Orphan, with Dublin-listed drug clinical trials manager Venn Life Sciences. The company rebranded as Hvivo in 2022.

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO 2024 Year in Review

    Discover how hVIVO Group’s innovative approach to human challenge trials and infectious disease expertise has shaped the future of pharmaceutical research in 2024.

    hVIVO plc

    Blood biomarkers for viral infection diagnosis and management

    Host response biomarkers to viral infections have significant potential in clinical applications, such as guiding diagnostic decisions, reducing unnecessary antibiotic use, and triggering infection control protocols or antiviral treatments. Research on these biomarkers has largely focused

    hVIVO plc

    Impact of patient perception on vaccine and drug efficacy

    Human viral challenge studies have become essential in evaluating the effectiveness of vaccines, treatments, and prophylactics, providing quicker results compared to larger Phase 2a/b field trials. hVIVO has developed various challenge agents for human use, including

    hVIVO plc

    Versatile MDCK cells in research and biotechnology

    MDCK (Madin-Darby Canine Kidney) cells are an essential tool in biological and medical research, especially in virology, cell biology, and studies involving membrane transport. Originally derived in 1958 from the kidney of a healthy adult female

    hVIVO plc

    Exploring the human viral challenge model for influenza research

    This study evaluates the human viral challenge model using the A/Perth/16/2009 H3N2 influenza virus, involving 216 volunteers across five clinical studies. Administered intranasally under controlled conditions, the research aimed to improve the understanding of influenza infection

    hVIVO plc

    Advancing influenza research with new challenge agents

    Controlled Human Infection Studies (CHIS) have proven to be essential in exploring human responses to respiratory infections and testing the effectiveness of vaccines and treatments. These studies hinge on selecting an appropriate challenge virus, making a

    hVIVO plc

    hVIVO’s patient enrolment & retention at Canary Wharf

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,